You have free access to this content

Cancer

Cover image for Cancer

Supplement: Perspectives in Bladder Cancer

15 April 2003

Volume 97, Issue S8

Pages 2049–2126

  1. Introduction

    1. Top of page
    2. Introduction
    1. You have free access to this content
    1. You have free access to this content
      Progress in the chemotherapy of metastatic cancer of the urinary tract (pages 2050–2055)

      Derek Raghavan

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11280

      This article reviews the recent progress in the management of advanced bladder cancer, with a specific focus on novel therapeutic strategies, the research agendas of the cooperative cancer research groups, and the applications of molecular technology to prognostication.

    2. You have free access to this content
      Review of a promising new agent—pemetrexed disodium (pages 2056–2063)

      Luis Paz-Ares, Susana Bezares, José M. Tabernero, Daniel Castellanos and Hernán Cortes-Funes

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11279

      The authors review results from numerous studies with pemetrexed disodium, which is a novel antifolate antimetabolite. Phase I–III trials, combination studies, and studies in patients with bladder cancer are described. Pemetrexed disodium exhibited significant antitumor activity in a wide range of solid tumors, including bladder cancer.

    3. You have free access to this content
      Current understanding of the biology of advanced bladder cancer (pages 2064–2075)

      Sana Al-Sukhun and Maha Hussain

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11289

      Transitional cell carcinoma (TCC) is the fifth most common solid tumor in the U.S. In the current report, the authors performed a comprehensive MEDLINE/PubMed search of articles pertaining to the biology of TCC from 1965 to the present from a clinical perspective, as well as a bibliographic review of cross-references.

    4. You have free access to this content
      Targeted therapy and pharmacogenomic programs (pages 2076–2082)

      Syma Iqbal and Heinz Josef Lenz

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11287

      The authors review the development and application of molecular markers and their application in gastrointestinal tumors. Targeted chemotherapy and pharmacogenomic programs are discussed along with technology that has been developed to profile tumors and predict response to particular chemotherapeutics.

    5. You have free access to this content
      Molecular targeting and pharmacogenomics in the management of advanced bladder cancer (pages 2083–2089)

      Derek Raghavan

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11281

      Considerable information exists regarding the molecular pathogenesis of bladder cancer and the genetic prognostic factors for natural history and response to treatment of this malignancy. This review summarizes what currently is known in these evolving domains.

    6. You have free access to this content
      Overview of bladder cancer trials in the Cancer and Leukemia Group B (pages 2090–2098)

      Eric J. Small, Susan Halabi, Guido Dalbagni, Raj Pruthi, George Phillips, Martin Edelman and Dean Bajorin

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11299

      The gemcitabine/cisplatin combination has become a commonly used regimen for the treatment of advanced transitional cell carcinoma (TCC). Novel agents, including arsenic trioxide and trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), are being evaluated as secondline therapy in patients with advanced TCC who have disease progression after frontline therapy.

    7. You have free access to this content
      Southwest Oncology Group studies in bladder cancer (pages 2099–2108)

      E. David Crawford, David P. Wood, Daniel P. Petrylak, Jennifer Scott, Charles A. Coltman Jr. and Derek Raghavan

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11286

      The Southwest Oncology Group (SWOG) Genitourinary Cancer Committee has studied therapeutic interventions in patients with superficial, invasive, and metastatic bladder cancer over the past 15 years, including six Phase III randomized trials. In this report, the authors highlight SWOG accomplishments and discuss future strategies for patients with bladder cancer.

    8. You have free access to this content
      Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group (pages 2109–2114)

      Robert Dreicer, Bruce Roth and George Wilding

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11298

      For more than 25 years, the Eastern Cooperative Oncology Group has been performing pilot and Phase II and III clinical trials comprising patients with advanced urothelial cancer. The authors present an overview of these studies and discuss future directions for management of this aggressive neoplasm.

    9. You have free access to this content
      Overview of bladder cancer trials in the Radiation Therapy Oncology Group (pages 2115–2119)

      William U. Shipley, Donald S. Kaufman, William J. Tester, Miljenko V. Pilepich and Howard M. Sandler

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11282

      The authors reviewed six bladder-sparing, prospective Radiation Therapy Oncology Group (RTOG) protocols of combined-modality therapy (intravesical surgery, chemotherapy, and radiation therapy) for patients with muscle-invasive bladder cancer, reserving radical cystectomy for incomplete responders. They also reviewed the current RTOG protocol and its successor, which include better tolerated and potentially more effective chemotherapy regimens.

    10. You have free access to this content
      Overview of bladder cancer trials in the European Organization for Research and Treatment (pages 2120–2126)

      Ronald de Wit

      Article first published online: 1 APR 2003 | DOI: 10.1002/cncr.11288

      The author reviews trials that were conducted in the 1990s by the European Organization for Research and Treatment of Cancer Genitourinary (EORTC GU) Group in patients with bladder cancer; and current, ongoing EORTC GU Group studies are described.

SEARCH

SEARCH BY CITATION